Top

Published in:

01-02-2015 | Original Article

Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS)

Authors: E. Gielen, T. O’Neill, S. Pye, J. Adams, K. Ward, F. Wu, M. Laurent, F. Claessens, S. Boonen, D. Vanderschueren, S. Verschueren

Published in: Osteoporosis International | Issue 2/2015

Abstract

Summary

The aim of this study was to determine whether bone turnover markers (BTMs) predict changes in areal bone mineral density (aBMD) in middle-aged and elderly European men. Older men with high bone turnover are at a higher risk of accelerated hip bone loss, but the clinical utility of BTMs in individuals is limited.

Introduction

Prospective studies on the value of BTMs to predict changes in aBMD in men are few and conflicting. The aim of this study was to determine whether BTMs predict changes in aBMD in middle-aged and elderly European men.

Methods

In 487 men aged 40–79 years from the European Male Ageing Study (EMAS), BTMs were assessed at baseline and dual-energy X-ray absorptiometry (DXA) at the lumbar spine (LS), femoral neck (FN) and total hip (TH) was performed at baseline and after a mean follow-up of 4.3 years.

Results

The mean aBMD decreased by 0.32 %/year at FN and 0.22 %/year at TH and increased by 0.32 %/year at LS. Higher baseline levels of β C-terminal cross-linked telopeptide (β-CTX) and N-terminal propeptide of type I procollagen (PINP) were significantly associated with higher loss of hip aBMD in the whole cohort and men aged 60–79 years. These associations remained significant after adjustment for age, centre and body mass index (BMI). Men aged 60–79 years with β-CTX in the upper quintile were more likely of being in the upper quintile of annual percentage (%) aBMD loss at FN (OR = 4.27; 95% CI = 2.09–8.73) and TH (OR = 3.73; 95% CI = 1.84–7.57). The positive predictive value (PPV) was 46 % at both hip sites.

Conclusion

Older men with high bone turnover have a higher risk of accelerated hip bone loss, but the PPV is low. BTMs are therefore unlikely to be of clinical utility in predicting accelerated hip bone loss in individual subjects.

Available only for authorised users

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733PubMedCrossRef

Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878–882PubMedCrossRef

Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29(4):441–464PubMedCentralPubMedCrossRef

Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, Group I-IBMSW (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391–420PubMedCrossRef

Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8(7):379–389PubMedCrossRef

Szulc P, Montella A, Delmas PD (2008) High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis 67(9):1249–1255PubMedCrossRef

Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E, Osteoporotic Fractures in Men Research G (2009) Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 24(12):2032–2038PubMedCentralPubMedCrossRef

Dennison E, Eastell R, Fall CH, Kellingray S, Wood PJ, Cooper C (1999) Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 10(5):384–391PubMedCrossRef

Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and 24 osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 20(4):579–587PubMedCrossRef

10.

Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C (1999) Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Calcif Tissue Int 65(3):198–202PubMedCrossRef

11.

Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2011) Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort. Mod Rheumatol 21(6):608–620PubMedCrossRef

12.

Scopacasa F, Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BE (2002) Bone density and bone-related biochemical variables in normal men: a longitudinal study. J Gerontol A: Biol Med Sci 57(6):M385–M391CrossRef

13.

Szulc P (2011) Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos 2011:704015PubMedCentralPubMedCrossRef

14.

Nguyen TV, Meier C, Center JR, Eisman JA, Seibel MJ (2007) Bone turnover in elderly men: relationships to change in bone mineral density. BMC Musculoskelet Disord 8:13PubMedCentralPubMedCrossRef

15.

Boonen S, Pye SR, O’Neill TW, Szulc P, Gielen E, Borghs H, Verschueren S, Claessens F, Adams JE, Ward KA, Bartfai G, Casanueva F, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Silman AJ, Tajar A, Wu FC, Vanderschueren D, Group E (2011) Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-aged and elderly European men: the European Male Ageing Study (EMAS). Eur J Endocrinol 165(6):977–986PubMedCrossRef

16.

Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, Tajar A, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, Wu FC, group Es (2009) The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 32(1):11–24PubMedCrossRef

17.

Lee DM, Pye SR, Tajar A, O’Neill TW, Finn JD, Boonen S, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Wu FC, Group ES (2013) Cohort profile: the European Male Ageing Study. Int J Epidemiol 42(2):391–401PubMedCrossRef

18.

Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46(2):153–162PubMedCrossRef

19.

Vanderschueren D, Pye SR, O’Neill TW, Lee DM, Jans I, Billen J, Gielen E, Laurent M, Claessens F, Adams JE, Ward KA, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Wu FC, Boonen S, Group ES (2013) Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab 98(3):995–1005PubMedCrossRef

20.

Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47(4):694–702PubMed

21.

Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54(1):188–196PubMedCrossRef

22.

Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J (2006) Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99(4–5):182–188PubMedCrossRef

23.

Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, Gomez J, Candas B, Chaussade V, Castiel I, Deloche C, Leclaire J (2007) Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 103(2):178–188PubMedCrossRef

24.

Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study G (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93(7):2737–2745PubMedCrossRef

25.

Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88(7):3075–3081PubMedCrossRef

26.

Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84(10):3666–3672PubMedCrossRef

27.

Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, Langdahl B, McLellan A, Pols H, Uitterlinden A, O’Riordan J, Wass JA, Ralston SH, Bennett ST (2006) Cross-calibration of dual-energy X-ray densitometers for a large, multi-center genetic study of osteoporosis. Osteoporos Int 17(1):125–132PubMedCrossRef

28.

Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359(9320):1841–1850PubMedCrossRef

29.

Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354(21):2250–2261PubMedCrossRef

30.

Seeman E (2003) Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int 14(Suppl 3):S2–S8PubMed

31.

Seeman E (2003) Invited review: pathogenesis of osteoporosis. J Appl Physiol (1985) 95(5):2142–2151

32.

Burger H, de Laet CE, van Daele PL, Weel AE, Witteman JC, Hofman A, Pols HA (1998) Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol 147(9):871–879PubMedCrossRef

33.

Cawthon PM, Ewing SK, McCulloch CE, Ensrud KE, Cauley JA, Cummings SR, Orwoll ES, Osteoporotic Fractures in Men Research G (2009) Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 24(10):1728–1735PubMedCentralPubMedCrossRef

34.

Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18(9):1297–1305PubMedCrossRef

35.

Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16(9):1642–1650PubMedCrossRef

36.

Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, Lucani B, Dal Canto N, Valenti R, Gennari C, Nuti R (2003) Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 88(11):5327–5333PubMedCrossRef

37.

Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean MEJ, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, Grp E (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–135PubMedCrossRef

Title: Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS)
Authors: E. Gielen
T. O’Neill
S. Pye
J. Adams
K. Ward
F. Wu
M. Laurent
F. Claessens
S. Boonen
D. Vanderschueren
S. Verschueren
Publication date: 01-02-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 2/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2884-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS)

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Associations between sedentary behaviour and body composition, muscle function and sarcopenia in community-dwelling older adults

Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton

Validation of a short questionnaire for estimating dietary calcium intakes

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort

Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective